Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SQM002
MIFTS: 45

Squamous Cell Papilloma

Categories: Cancer diseases, Oral diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Squamous Cell Papilloma

About this section

MalaCards integrated aliases for Squamous Cell Papilloma:

Name: Squamous Cell Papilloma 12 15
Papilloma 44 70
Papilloma, Squamous Cell 70
Epidermoid Papilloma 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Skin diseases Oral diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:139
MeSH 44 D010212
NCIt 50 C3712
SNOMED-CT 67 63451008
UMLS 70 C0030354 C0205874
Sources

Summaries for Squamous Cell Papilloma

About this section
MalaCards based summary : Squamous Cell Papilloma, also known as papilloma, is related to skin papilloma and papillary adenoma. An important gene associated with Squamous Cell Papilloma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Human T-cell leukemia virus 1 infection and Viral carcinogenesis. The drugs Chlorhexidine and Polihexanide have been mentioned in the context of this disorder. Affiliated tissues include skin, cervix and breast, and related phenotype is neoplasm.

Wikipedia : 73 A squamous cell papilloma is a generally benign papilloma that arises from the stratified squamous... more...

Sources

Related Diseases for Squamous Cell Papilloma

About this section

Diseases related to Squamous Cell Papilloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 850)
# Related Disease Score Top Affiliating Genes
1 skin papilloma 32.1 TP53 KRT14 HRAS
2 papillary adenoma 32.1 TP53 HRAS
3 inverted papilloma 31.8 TP53 CDKN2A
4 human papillomavirus infectious disease 31.8 TP53 CDKN2A
5 li-fraumeni syndrome 31.5 TP53 HRAS CDKN2A
6 papilloma 31.5 TP53 KRT14 CDKN2A
7 suppressor of tumorigenicity 3 31.4 TP53 CDKN2A
8 anogenital venereal wart 31.3 TP53 GP5 CDKN2A
9 cervical cancer 31.1 TP53 KRT14 HRAS CDKN2A
10 penile cancer 31.0 TP53 HRAS GP5 CDKN2A
11 transitional cell carcinoma 30.9 TP53 HRAS CDKN2A
12 in situ carcinoma 30.8 TP53 KRT14 HRAS CDKN2A
13 cervix uteri carcinoma in situ 30.8 TP53 GP5 CDKN2A
14 ductal carcinoma in situ 30.6 TP53 KRT14 CDKN2A
15 cervicitis 30.4 GP5 CDKN2A
16 vulvar intraepithelial neoplasia 30.4 TP53 CDKN2A
17 bladder urothelial carcinoma 30.3 TP53 HRAS CDKN2A
18 actinic keratosis 30.3 TP53 HRAS CDKN2A
19 basaloid squamous cell carcinoma 30.2 TP53 KRT14 CDKN2A
20 epidermodysplasia verruciformis 1 30.1 TP53 KRT14 GP5
21 anal squamous cell carcinoma 30.1 TP53 CDKN2A
22 mucoepidermoid carcinoma 30.1 TP53 KRT14 CDKN2A
23 chronic cervicitis 30.0 TP53 GP5 CDKN2A
24 carcinosarcoma 30.0 TP53 HRAS CDKN2A
25 hypopharynx cancer 29.9 TP53 CDKN2A
26 anus cancer 29.9 TP53 HRAS GP5 CDKN2A
27 tonsil cancer 29.9 TP53 KRT14 CDKN2A
28 skin carcinoma 29.9 TP53 KRT14 HRAS CDKN2A
29 esophagus verrucous carcinoma 29.9 TP53 CDKN2A
30 acanthoma 29.8 TP53 CDKN2A
31 large cell acanthoma 29.8 TP53 KRT14
32 keratinizing squamous cell carcinoma 29.8 TP53 CDKN2A
33 ameloblastic carcinoma 29.8 KRT14 CDKN2A
34 vulvar dystrophy 29.8 TP53 CDKN2A
35 adenoid cystic carcinoma 29.8 TP53 KRT14 HRAS CDKN2A
36 vaginal cancer 29.7 TP53 GP5 CDKN2A
37 lung squamous cell carcinoma 29.7 TP53 HRAS CDKN2A
38 skin disease 29.6 TP53 KRT14 HRAS ATP2A2
39 sebaceous adenocarcinoma 29.6 TP53 KRT14
40 lung adenoma 29.6 TP53 HRAS CDKN2A
41 lung benign neoplasm 29.6 TP53 HRAS CDKN2A
42 skin squamous cell carcinoma 29.6 TP53 HRAS CDKN2A
43 suppression of tumorigenicity 12 29.6 TP53 HRAS CDKN2A
44 giant cell glioblastoma 29.6 TP53 HRAS CDKN2A
45 vulva squamous cell carcinoma 29.6 TP53 GP5 CDKN2A
46 cervix carcinoma 29.5 TP53 GP5 CDKN2A
47 gastric adenocarcinoma 29.5 TP53 HRAS CDKN2A
48 comedo carcinoma 29.5 TP53 GP5
49 oropharynx cancer 29.4 TP53 KRT14 HRAS GP5 CDKN2A
50 keratosis 29.3 TP53 KRT14 HRAS CDKN2A ATP2A2

Graphical network of the top 20 diseases related to Squamous Cell Papilloma:



Diseases related to Squamous Cell Papilloma
Sources

Symptoms & Phenotypes for Squamous Cell Papilloma

About this section

MGI Mouse Phenotypes related to Squamous Cell Papilloma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 ATP2A2 CDKN2A HRAS KRT14 NQO2 TP53
Sources

Drugs & Therapeutics for Squamous Cell Papilloma

About this section

Drugs for Squamous Cell Papilloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
2
Polihexanide Approved, Investigational Phase 4 28757-47-3
3 Chlorhexidine gluconate Phase 4
4 Anti-Infective Agents, Local Phase 4
5 Disinfectants Phase 4
6 Hypoglycemic Agents Phase 4
7 Biguanides Phase 4
8
Azithromycin Approved Phase 3 83905-01-5 447043 55185
9
Penicillin G Approved, Vet_approved Phase 3 61-33-6 5904
10
Fluorouracil Approved Phase 3 51-21-8 3385
11 Antibiotics, Antitubercular Phase 3
12 Anti-Bacterial Agents Phase 3
13 Penicillin G Procaine Phase 3
14 Penicillin G Benzathine Phase 3
15 Immunosuppressive Agents Phase 3
16 Antimetabolites Phase 3
17 Anesthetics Phase 3
18
Cidofovir Approved Phase 2 113852-37-2 60613
19
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
20
Mycophenolic acid Approved Phase 2 24280-93-1 446541
21
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
22
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
23
Masoprocol Approved, Investigational Phase 1, Phase 2 27686-84-6, 500-38-9 71398
24
Catechin Approved, Withdrawn Phase 2 154-23-4 9064
25
Lenograstim Approved, Investigational Phase 2 135968-09-1
26
Nelfinavir Approved Phase 2 159989-64-7 64143
27
nivolumab Approved Phase 2 946414-94-4
28
Hydroxyurea Approved Phase 2 127-07-1 3657
29
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
30
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
31
Pembrolizumab Approved Phase 2 1374853-91-4
32
Lenvatinib Approved, Investigational Phase 2 417716-92-8
33
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
34
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
35
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
36
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
37
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
38
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
39
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4 445354
40
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
41
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
42
Aspartic acid Approved, Nutraceutical Phase 1, Phase 2 56-84-8 5960
43
Epigallocatechin gallate Investigational Phase 2 989-51-5 65064
44
Epicatechin Investigational Phase 2 490-46-0 72276
45
Epigallocatechin Experimental, Investigational Phase 2 970-74-1 72277
46 Olive Phase 2
47 Pharmaceutical Solutions Phase 2
48 retinol Phase 2
49 Retinol palmitate Phase 2
50
Erlotinib Hydrochloride Phase 2 183319-69-9 176871

Interventional clinical trials:

(show top 50) (show all 229)
# Name Status NCT ID Phase Drugs
1 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Completed NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
2 Antisepsis Regimen in the Surgical Treatment of Human Papilloma Virus Generated Cervical Lesions: Polyhexamethylene Biguanide Versus Chlorhexidine Completed NCT01740245 Phase 4
3 Use of Cidofovir Injection in the Treatment of Recurrent Respiratory Papillomatosis." Completed NCT00205374 Phase 4 Cidofovir;Placebo
4 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination (Version IV Dated 24Oct2017) Recruiting NCT03350698 Phase 4
5 A Pilot Study of the Immunogenicity of a Two-dose Protocol for 9-valent Human Papilloma Virus Vaccination in Postpartum Girls and Women (15-45 Years Old) Previously Unvaccinated Against HPV Recruiting NCT04274153 Phase 4
6 Study of the Impact of a School Program Combining - Promotion of HPV Vaccination and HPV Vaccine Offer in Middle School - on Adherence to HPV Vaccination in Middle School Students Recruiting NCT04459221 Phase 4 Gardasil 9, 9-Valent Intramuscular Suspension
7 Prospective Longitudinal Study on Immunogenicity, Induction of Cellular Immune Responses and Safety of Vaccination Against HPV With the 9-valent Vaccine in HIV-positive Women (The Papillon Study) Recruiting NCT03391921 Phase 4
8 Randomized, Placebo-controlled, Double-blind Study to Evaluate 2LPAPI® Efficacy on the Clearance of Genital HR-HPV Infections. Recruiting NCT04232917 Phase 4 2LPAPI®;Placebo
9 GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose Recruiting NCT03943875 Phase 4
10 Immunogenicity, Compliance, Knowledge and Attitudes in Postpartum Women During a Two Dose 9-valent HPV Vaccination Series Not yet recruiting NCT04311528 Phase 4
11 Assessment of the Safety, Side Effects and Efficacy of Interventional Cryotherapy for the Eradication of Benign Airway Disease("ICE THE BAD") Terminated NCT00747461 Phase 4
12 The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) Withdrawn NCT04183738 Phase 4 NRTIs;Darunavir;Ritonavir;Dolutegravir
13 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
14 Evaluation of a Two-dose Schedule of Quadrivalent Human Papilloma Virus (Types 6, 11, 16, 18) Recombinant Vaccine in 11-year-old Boys in Mexico City (Gardasil® Merck and Co.). Unknown status NCT02382900 Phase 3
15 Efficacy Study of the Quadrivalent Human Papilloma Virus (HPV) Vaccine to Prevent Recurrence of External Genital Warts (EGW) in Patients Who Were Cured in the First Place Unknown status NCT03296397 Phase 3
16 A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of HPV-16/18 Vaccine in Healthy Females Aged 18-30 Years Unknown status NCT02733068 Phase 3
17 Phase III, Single-center Clinical Trial to Evaluate the 4-valent HPV Vaccine for the Treatment and Prevention of Recurrent Respiratory Papillomatosis in Children Unknown status NCT01995721 Phase 3
18 Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea Completed NCT01955252 Phase 3 Azithromycin
19 Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study Completed NCT00090220 Phase 3
20 Prospective Non Controlled Study of Immunogenicity of Human Papilloma Virus (HPV) Vaccine in Groups at Special Risk of Poor Vaccine Result Completed NCT00964210 Phase 3 Licensed quadrivalent HPV vaccine, Gardasil
21 An Open-label Phase III Study to Investigate the Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine (Gardasil®9) in Solid Organ Transplant Recipients and HIV-infected Patients Completed NCT03525210 Phase 3
22 A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese Men Completed NCT01862874 Phase 3
23 A Phase III, Open-Label, Clinical Trial to Study the Safety and Immunogenicity of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP Particle (VLP) Vaccine in 9- to 15-Year-Old Japanese Boys Completed NCT02576054 Phase 3
24 Phase IIIb Study of Recombinant Tetravalent HPV Vaccine in Patients With Recurrent Respiratory Papillomatosis Completed NCT01375868 Phase 3
25 A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [HPV] [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus L1 Virus-Like Particle [VLP] Vaccine) in 16- to 26-year-old Men Completed NCT02114385 Phase 3
26 ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study Recruiting NCT02135419 Phase 3 imiquimod;fluorouracil
27 A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls Active, not recruiting NCT02834637 Phase 3 bivalent HPV vaccine;nonavalent HPV vaccine
28 Adjuvant Imiquimod Therapy to Reduce Recurrence Rate in Patients After Surgical Therapy of Anal HPV (Human Papilloma Virus)-Lesions Not yet recruiting NCT03289260 Phase 3 Imiquimod 5% cream;Placebo cream
29 Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis Withdrawn NCT01058317 Phase 2, Phase 3 Propranolol
30 Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx Unknown status NCT00002454 Phase 2
31 Single Center, Placebo Controlled, Double-Blind Study to the Treatment of HPV Infected Cervix With AV2 Antiviral Spray and Assessment of Viral Load Unknown status NCT01654822 Phase 2 topical application cervical spray;topical spray on the cervix
32 Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT02555800 Phase 2 Bevacizumab;Cidofovir
33 A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRXâ„¢ Anorectal Wand Unknown status NCT03302858 Phase 2
34 A Phase II Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib, in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck Completed NCT00720304 Phase 2 docetaxel;erlotinib hydrochloride
35 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
36 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
37 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
38 Phase II Pilot Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low Dose TBI and Post-Transplant Cyclosporine and Mycophenolate Mofetil Followed by Donor Lymphocyte Infusion for Therapy of Advanced or Metastatic Human Papilloma Virus (HPV) - Associated Cervical Carcinoma Refractory to Standard Therapy Completed NCT00005941 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
39 Efficacy and Safety of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal. Phase II Clinical Trial Completed NCT03584308 Phase 2
40 A Pilot Translational Study of Tetra-O-Methyl Nordihydroguaiaretic Acid (EM-1421) for the Treatment of Cervical Intraepithelial Neoplasia Induced by Human Papilloma Virus Completed NCT00154089 Phase 1, Phase 2 EM-1421
41 A Phase II Trial in Patients With Early Cervical Cancer to Study The Safety and The Immunological Effects of Vaccination With TA-HPV, A Live Recombinant Vaccinia Virus Expressing The Human Papilloma Virus 16 and 18 E6 and E7 Proteins Completed NCT00002916 Phase 2
42 A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer Completed NCT02159703 Phase 2
43 A Multicenter, Open Label Phase I/II Study to Determine the Safety and Immune Modulating Effects of the Therapeutic Human Papilloma Virus 16 (HPV16) E6/E7 Long Peptides Vaccine (ISA101/ISA101b) Immunotherapy in Combination With Standard of Care Therapy (Carboplatin and Paclitaxel With or Without Bevacizumab) in Women With HPV16 Positive Advanced or Recurrent Cervical Cancer Who Have no Curative Treatment Options Completed NCT02128126 Phase 1, Phase 2 ISA101/ISA101b
44 A Phase IIa Randomized, Double-Blind Controlled With Gardasil, Clinical Trial to Study theTolerability and Immunogenicity of V505 (a Multivalent Human Papilloma Virus [HPV] L1 Virus Like Particle [VLP] Vaccine) in Healthy 16 to 26 Year Old Women Completed NCT00520598 Phase 2 Comparator: V505 formulation 2;Comparator: V505 formulation 2
45 A Phase II Trial of SGN-00101 In The Treatment of Pediatric Recurrent Respiratory Papillomatosis Completed NCT00038714 Phase 2 SGN-00101
46 Phase II Trial Of Induction Chemotherapy Followed By Attenuated Chemoradiotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma Associated With Human Papillomavirus (HPV) Completed NCT02048020 Phase 2 paclitaxel;carboplatin
47 Phase II Evaluation Of SGN-00101 (HSP-E7) Fusion Protein In Women With Cervical Intraepithelial Neoplasia 3, CIN 3 Completed NCT00054041 Phase 2
48 A Phase II Trial of Polyphenon E for Cervical Cancer Prevention Completed NCT00303823 Phase 2 placebo
49 Evaluation of Natural Human Interferon Alpha Administered Oromucosally in the Treatment of Oral Warts in HIV-seropositive Subjects Receiving Combination Anti-retroviral Therapy: A Phase 2 Clinical Trial Completed NCT00454181 Phase 2 Interferon-alpha
50 Study of the Safety and Effectiveness of Candin for the Treatment of Common Warts Completed NCT01757392 Phase 2

Search NIH Clinical Center for Squamous Cell Papilloma

Inferred drug relations via UMLS 70 / NDF-RT 51 :


podophyllin
PODOPHYLLIN PWDR

Cochrane evidence based reviews: papilloma

Sources

Genetic Tests for Squamous Cell Papilloma

About this section
Sources

Anatomical Context for Squamous Cell Papilloma

About this section

MalaCards organs/tissues related to Squamous Cell Papilloma:

40
Skin, Cervix, Breast, Tongue, T Cells, Endothelial, Prostate
Sources

Publications for Squamous Cell Papilloma

About this section

Articles related to Squamous Cell Papilloma:

(show top 50) (show all 14536)
# Title Authors PMID Year
1
Electrochemical diagnostics of infectious viral diseases: Trends and challenges. 61
33706158 2021
2
Internet of medical things (IoMT)-integrated biosensors for point-of-care testing of infectious diseases. 61
33596516 2021
3
Role of circRNAs in viral infection and their significance for diagnosis and treatment (Review). 61
33786618 2021
4
False-Positive Uptake of 131I From Basal Cell Papilloma in a Patient With Metastatic Papillary Thyroid Cancer. 61
33492860 2021
5
Identification of the Knowledge Level of Students Receiving Health Education About the Human Papilloma Virus, Screening Tests, and Human Papilloma Virus Vaccination. 61
32683532 2021
6
Squamous cell carcinoma superimposed on mucosal leishmaniasis in an HIV-positive patient. 61
33570462 2021
7
Mucinous adenocarcinoma caused by cancerization from a ciliated multinodular papilloma tumor: A case report. 61
33811447 2021
8
ER-positive endocervical adenocarcinoma mimicking endometrioid adenocarcinoma in morphology and immunohistochemical profile: A case report of application of HPV RNAscope detection. 61
33787580 2021
9
Upgrade rate of intraductal papilloma diagnosed on core needle biopsy in a single institution. 61
33159966 2021
10
Human papilloma virus vaccination in males: A pharmacovigilance study on the Vaccine Adverse Event Reporting System. 61
33145777 2021
11
Storz Professional Image Enhancement System (SPIES) endoscopy in the detection of sinonasal inverted papilloma: a pilot study. 61
33794734 2021
12
Human Papilloma Virus 18-Positive Submucosal Small Cell Neuroendocrine Carcinoma of the Vagina: An Immunohistochemical and Genomic Study. 61
33792412 2021
13
Management of FDG avid Benign Sinonasal Schneiderian Papilloma: A Case Report and Review of the Literature. 61
32847383 2021
14
Inverted Nasal Papilloma Affecting Ears and Pulmonary Parenchyma: Case Report. 61
33811658 2021
15
Surgical Margin Determination in the Era of HPV-Positive Oropharyngeal Cancer. 61
33797105 2021
16
TERT promoter mutations in penile squamous cell carcinoma: high frequency in non-HPV-related type and association with favorable clinicopathologic features. 61
33635430 2021
17
Diagnostic utility of p16 immunocytochemistry in metastatic cervical lymph nodes in head and neck cancers. 61
33428334 2021
18
Clinical and pathological diagnosis and comparison of benign and malignant eyelid tumors. 61
33610396 2021
19
The role of Tim-3/Galectin-9 pathway in T-cell function and prognosis of patients with human papilloma virus-associated cervical carcinoma. 61
33559190 2021
20
Distinction between vaginal and cervical microbiota in high-risk human papilloma virus-infected women in China. 61
33765914 2021
21
The Effect of Indian Fig Fruit Extract on Human Papilloma Virus containing Cervical Cancer Cells (HeLa) by Decreasing the HPV18 L1 Gene Load. 61
33773542 2021
22
Intra-fourth-ventricular choroid plexus papilloma miming ependymoma. 61
33763674 2021
23
Pediatric choroid plexus papilloma arising from the cerebellopontine angle: systematic review with illustrative case. 61
32980905 2021
24
Mobile Applications: Breaking Barriers to Early Breast and Cervical Cancer Detection in Underserved Communities. 61
33417491 2021
25
Molecular and biological functions of gingerol as a natural effective therapeutic drug for cervical cancer. 61
33706784 2021
26
The Silva Pattern-based Classification for HPV-associated Invasive Endocervical Adenocarcinoma and the Distinction Between In Situ and Invasive Adenocarcinoma: Relevant Issues and Recommendations From the International Society of Gynecological Pathologists. 61
33570863 2021
27
High-grade Neuroendocrine Carcinomas of the Vulva: A Clinicopathologic Study of 16 Cases. 61
32826525 2021
28
Vaccine hesitancy and reported non-vaccination in an Irish pediatric outpatient population. 61
33774718 2021
29
High-Risk Lesions Detected by MRI-Guided Core Biopsy: Upgrade Rates at Surgical Excision and Implications for Management. 61
33439046 2021
30
The nipple-areolar complex: comprehensive imaging review. 61
33077158 2021
31
Diagnostic value of sialyl-Tn immunocytochemistry in breast cancer presenting with pathological nipple discharge. 61
33605547 2021
32
A rare case of nevus sebaceous of the bilateral labia minora: A case report and review of literature. 61
33725889 2021
33
Frequent high-risk HPV co-infections excluding types 16 or 18 in cervical neoplasia in Guadeloupe. 61
33726684 2021
34
The evaluation of Human papilloma virus and human herpes viruses (EBV, CMV, VZV HSV-1 and HSV-2) in semen samples. 61
33774857 2021
35
Well-differentiated neuroendocrine tumors of the lower urinary tract: biologic behavior of a rare entity. 61
33301750 2021
36
Combined In Situ Hybridization and Immunohistochemistry on Archival Tissues Reveals Stromal microRNA-204 as Prognostic Biomarker for Oral Squamous Cell Carcinoma. 61
33804049 2021
37
circPHIP promotes oral squamous cell carcinoma progression by sponging miR-142-5p and regulating PHIP and ACTN4 expression. 61
33376626 2021
38
Paraneoplastic Conjunctival Acanthosis Nigricans: A Case Report. 61
32991358 2021
39
Inverted urothelial papilloma: A rare pathology in young girl. A case report and literature review. 61
33384936 2021
40
Sialadenoma Papilliferum. 61
33526222 2021
41
Socioeconomic Factors Influence the Impact of Tumor HPV Status on Outcome of Patients With Oropharyngeal Squamous Cell Carcinoma. 61
33434083 2021
42
Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. 61
33417831 2021
43
German evidence and consensus-based (S3) guideline: Vaccination recommendations for the prevention of HPV-associated lesions. 61
33634583 2021
44
Knowledge of Chinese dentists on HPV, their willingness and barriers to recommend HPV vaccination to patients. 61
33687314 2021
45
Epstein-Barr virus may contribute to the pathogenesis of adult-onset recurrent respiratory papillomatosis: A preliminary study. 61
33263360 2021
46
Benefit of postoperative radiotherapy in patients with oropharyngeal squamous cell carcinoma in human papillomavirus (HPV) era: A Surveillance, Epidemiology, and End Results (SEER) database analysis. 61
33663877 2021
47
An Experimental Model of Human Recurrent Respiratory Papillomatosis: A Bridge to Clinical Insights. 61
32894613 2021
48
Sublesional Bevacizumab Injection for Recurrent Respiratory Papillomatosis: Evaluation of Utility in a Typical Clinical Practice. 61
33648353 2021
49
Human papilloma virus and vaccine: knowledge and acceptability in an Irish general hospital-a questionnaire-based study. 61
33770353 2021
50
Human Papilloma Virus vaccine and prevention of head and neck cancer, what is the current evidence? 61
33730628 2021
Sources

Variations for Squamous Cell Papilloma

About this section
Sources

Expression for Squamous Cell Papilloma

About this section
Search GEO for disease gene expression data for Squamous Cell Papilloma.
Sources

Pathways for Squamous Cell Papilloma

About this section

Pathways related to Squamous Cell Papilloma according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Human T-cell leukemia virus 1 infection 36
12.01 TP53 HRAS CDKN2A
2
Viral carcinogenesis 36
11.94 TP53 HRAS CDKN2A
3
Cellular senescence (KEGG) 36
11.74 TP53 HRAS CDKN2A
4
Thyroid hormone signaling pathway 36
11.58 TP53 HRAS ATP2A2
5
DNA Damage Response (only ATM dependent) 1
11.49 TP53 HRAS CDKN2A
6
Glioblastoma Multiforme 63
11.38 TP53 HRAS CDKN2A
7
Senescence and Autophagy in Cancer 1
11.16 TP53 HRAS CDKN2A
8
Oncogene Induced Senescence 65
10.98 TP53 CDKN2A
9
TP53 Network 1
Show member pathways
 10.78 TP53 CDKN2A
10
Inhibition of Ribosome Biogenesis by p14(ARF) 63
10.75 TP53 CDKN2A
11
Bladder cancer 36 1
10.66 TP53 HRAS CDKN2A
Sources

GO Terms for Squamous Cell Papilloma

About this section

Biological processes related to Squamous Cell Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell cycle arrest GO:0071158 9.46 TP53 CDKN2A
2 positive regulation of reactive oxygen species metabolic process GO:2000379 9.43 TP53 NQO2
3 intrinsic apoptotic signaling pathway GO:0097193 9.4 TP53 HRAS
4 cellular response to gamma radiation GO:0071480 9.37 TP53 HRAS
5 cell cycle arrest GO:0007050 9.33 TP53 HRAS CDKN2A
6 cell aging GO:0007569 9.32 TP53 HRAS
7 cellular senescence GO:0090398 9.26 HRAS CDKN2A
8 replicative senescence GO:0090399 8.96 TP53 CDKN2A
9 Ras protein signal transduction GO:0007265 8.8 TP53 HRAS CDKN2A

Molecular functions related to Squamous Cell Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MDM2/MDM4 family protein binding GO:0097371 8.62 TP53 CDKN2A
Sources

Sources for Squamous Cell Papilloma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....